UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

Cancer research (Chicago, Ill.), 2009-09, Vol.69 (17), p.6871-6878

2009

Volltextzugriff (PDF)

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma

Cell reports (Cambridge), 2013-09, Vol.4 (6), p.1090-1099

2013

Volltextzugriff (PDF)

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

Cancer research (Chicago, Ill.), 2006-02, Vol.66 (3), p.1630-1639

2006

Volltextzugriff (PDF)

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

Molecular cancer therapeutics, 2007-07, Vol.6 (7), p.2012-2021

2007

Volltextzugriff (PDF)

Inhibition of the Growth of Patient-Derived Pancreatic Cancer Xenografts with the MEK Inhibitor Trametinib Is Augmented by Combined Treatment with the Epidermal Growth Factor Receptor/HER2 Inhibitor Lapatinib

Neoplasia (New York, N.Y.), 2013-02, Vol.15 (2), p.143-IN10

2013

Volltextzugriff (PDF)

Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles

Molecular cancer therapeutics, 2007-05, Vol.6 (5), p.1629-1640

2007

Volltextzugriff (PDF)

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1

Molecular cancer therapeutics, 2007-02, Vol.6 (2), p.450-459

2007

Volltextzugriff (PDF)

Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib

Cancer research (Chicago, Ill.), 2008-01, Vol.68 (2), p.571-579

2008

Volltextzugriff (PDF)

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

Molecular cancer therapeutics, 2012-04, Vol.11 (4), p.909-920

2012

Volltextzugriff (PDF)

Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data

Clinical cancer research, 2008-12, Vol.14 (23), p.7900-7908

2008

Volltextzugriff (PDF)

A Novel Dual ATM/DNA-PK Inhibitor, XRD-0394, Potently Radiosensitizes and Potentiates PARP and Topoisomerase I Inhibitors

Molecular cancer therapeutics, 2024-06, p.OF1-OF15

2024

Volltextzugriff (PDF)

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

Cancer research (Chicago, Ill.), 2004-09, Vol.64 (18), p.6652-6659

2004

Volltextzugriff (PDF)

Identification of Both Positive and Negative Domains within the Epidermal Growth Factor Receptor COOH-terminal Region for Signal Transducer and Activator of Transcription (STAT) Activation

The Journal of biological chemistry, 2002-08, Vol.277 (34), p.30716-30723

2002

Volltextzugriff (PDF)

Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells

Molecular cancer therapeutics, 2011-03, Vol.10 (3), p.518-530

2011

Volltextzugriff (PDF)

Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Cancer research (Chicago, Ill.), 2008-04, Vol.68 (7), p.2366-2374

2008

Volltextzugriff (PDF)

The discovery of lapatinib (GW572016)

Molecular cancer therapeutics, 2011-11, Vol.10 (11), p.2019-2019

2011

Volltextzugriff (PDF)

Lapatinib: functional genomics study leads to insights into mechanism of action

Molecular cancer therapeutics, 2011-11, Vol.10 (11), p.2025-2025

Gilmer, Tona M

2011

Volltextzugriff (PDF)

The Translational Research Working Group Developmental Pathway for Anticancer Agents (Drugs or Biologics)

Clinical cancer research, 2008-09, Vol.14 (18), p.5685-5691

2008

Volltextzugriff (PDF)

The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo

Molecular cancer therapeutics, 2001-12, Vol.1 (2), p.85-94

2001

Volltextzugriff (PDF)

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer

Cancer research (Chicago, Ill.), 2001-10, Vol.61 (19), p.7196-7203

2001

Volltextzugriff (PDF)

Effect of Lapatinib on the Development of Estrogen Receptor–Negative Mammary Tumors in Mice

JNCI : Journal of the National Cancer Institute, 2009-01, Vol.101 (2), p.107-113

2009

Volltextzugriff (PDF)

Interaction of the p53-Regulated Protein Gadd45 with Proliferating Cell Nuclear Antigen

Science (American Association for the Advancement of Science), 1994-11, Vol.266 (5189), p.1376-1380

1994

Volltextzugriff (PDF)

Induction of Gene Amplification by Arsenic

Science (American Association for the Advancement of Science), 1988-07, Vol.241 (4861), p.79-81

1988

Volltextzugriff (PDF)

W1949 C-MET Amplification in Oesophageal Adenocarcinoma Cell Lines Influences EGFR and Erbb2 Phosphorylation Status and May Provide Resistance to ERBB Targeted Therapies

Gastroenterology (New York, N.Y. 1943), 2008, Vol.134 (4), p.A-740-A-740

2008

Volltextzugriff (PDF)

Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines

Bioorganic & medicinal chemistry letters, 2003-02, Vol.13 (4), p.637-640

2003

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(73)

Publikationsform

Artikel
(80)

Sprache

Englisch
(80)

Erscheinungsjahr

n.n

Thema

Science & Technology
(53)
Life Sciences & Biomedicine
(49)
Humans
(38)
Oncology
(28)
Biological And Medical Sciences
(27)
Animals
(26)
Medical Sciences
(19)
Female
(17)
Mice
(16)
Tumors
(15)
Cell Line
(13)
Pharmacology. Drug Treatments
(12)
Quinazolines - Pharmacology
(12)
Antineoplastic Agents
(11)
Antineoplastic Agents - Pharmacology
(10)
Biochemistry & Molecular Biology
(10)
Cell Line, Tumor
(10)
Oncogenes
(10)
Fundamental And Applied Biological Sciences. Psychology
(8)
Phosphorylation
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

Inhibition of the Growth of Patient-Derived Pancreatic Cancer Xenografts with the MEK Inhibitor Trametinib Is Augmented by Combined Treatment with the Epidermal Growth Factor Receptor/HER2 Inhibitor Lapatinib

Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles

In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1

Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data

A Novel Dual ATM/DNA-PK Inhibitor, XRD-0394, Potently Radiosensitizes and Potentiates PARP and Topoisomerase I Inhibitors

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

Identification of Both Positive and Negative Domains within the Epidermal Growth Factor Receptor COOH-terminal Region for Signal Transducer and Activator of Transcription (STAT) Activation

Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells

Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

The discovery of lapatinib (GW572016)

Lapatinib: functional genomics study leads to insights into mechanism of action

The Translational Research Working Group Developmental Pathway for Anticancer Agents (Drugs or Biologics)

The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer

Effect of Lapatinib on the Development of Estrogen Receptor–Negative Mammary Tumors in Mice

Interaction of the p53-Regulated Protein Gadd45 with Proliferating Cell Nuclear Antigen

Induction of Gene Amplification by Arsenic

W1949 C-MET Amplification in Oesophageal Adenocarcinoma Cell Lines Influences EGFR and Erbb2 Phosphorylation Status and May Provide Resistance to ERBB Targeted Therapies

Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines

Suchergebnisse filtern